Cryo Cell International (CCEL) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended August 31, 2025 was $23.7M, down slightly from $24.0M year-over-year, with a 3% increase in recurring annual storage fees offset by a 14% decrease in new domestic cord blood specimens processed.

• Fiscal third quarter 2025 revenue was $7.83 million, a 3% decrease year-over-year from $8.07 million.

• Net income for the nine months was $1.39M, down from $2.26M in the prior year period, reflecting higher legal expenses and lower gains on marketable securities.

• Net income for the quarter was $749,000, or $0.09 per share, down from $1.05 million, or $0.13 per share, in the prior year period.

• The company is engaged in arbitration with Duke University over a terminated license agreement, pausing expansion plans and the proposed Celle Corp. spinoff.

Financial highlights

• Operating income for the nine months was $4.45M, up from $3.60M year-over-year.

• Cost of sales decreased 11% to $5.64M, while selling, general and administrative expenses rose 2% to $12.77M, mainly due to increased legal fees.

• Interest expense increased to $1.58M from $1.12M, reflecting higher debt balances and rates.

• Losses on marketable securities were $0.60M, compared to gains of $1.06M in the prior year.

• Cash and cash equivalents at period end were $0.27M, down from $0.56M at the prior year-end.

Outlook and guidance

• The company anticipates sufficient liquidity for at least the next 12 months, but future capital needs depend on the outcome of the Duke arbitration.

• Planned capital expenditures of $1M over the next year for equipment and software enhancements.

• No further investments in Duke-related activities are planned until the dispute is resolved.